EUVIMEDOpdag EUVIMED
Video/AudioÜbersichtsarbeit

Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease Beyond Fibrosis: Metabolic, Microbial, and Immune Determinants​

Zheng-Ying Wang, Cheng-Cheng Song, Yan Jiao

Journal of Visualized Experiments · 2026

DOI: 10.3791/73743 ↗

At a glance

Video/Audio in Journal of Visualized Experiments, 2026. Written by Zheng-Ying Wang and 2 co-authors. Institution: Department of Comprehensive Surgery, The First Hospital of Jilin University. Major MEDLINE topics: Carcinoma, Hepatocellular, Fatty Liver, Liver Neoplasms, Metabolic Diseases.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly important cause of hepatocellular carcinoma (HCC). Fibrosis and cirrhosis remain the best-validated predictors of HCC, yet a substantial minority of MASLD-related tumors are diagnosed without cirrhosis. This narrative review evaluates what 'beyond fibrosis' should mean for risk assessment rather than treating fibrosis as dispensable. We first separate the proportion of HCC cases that are noncirrhotic from the much lower absolute incidence of HCC in the noncirrhotic MASLD population. We then synthesize human, animal, and in vitro evidence for lipotoxic and oxidative injury, insulin and insulin-like growth factor signaling, gut-liver communication, and immune remodeling. We distinguish plausible mechanistic drivers from clinical risk modifiers, future-risk biomarkers, early detection tests, and disease-modifying interventions. Current evidence supports fibrosis-centered, layered risk stratification using clinical factors and noninvasive fibrosis measures, whereas genetic, proteomic, microbial, and immune markers remain investigational. Resmetirom and semaglutide improve MASH histology in selected noncirrhotic patients with F2-F3 fibrosis; evidence for direct HCC prevention by metabolic drugs or bariatric surgery remains observational or absent. Routine surveillance is not justified for MASLD without advanced fibrosis, but individualized evaluation in F3 disease and prospective validation of multivariable risk models are priorities.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularFatty LiverLiver NeoplasmsMetabolic DiseasesAnimalsHumansLiver Cirrhosis

Authors and institutions

  • Department of Comprehensive Surgery, The First Hospital of Jilin University.
  • Changchun Jirun Jingyue Hospital, The First Hospital of Jilin University.
  • Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University; jiaoyan@jlu.edu.cn.

Cite

APA

Wang, Z. Y., Song, C. C., & Jiao, Y. (2026). Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease Beyond Fibrosis: Metabolic, Microbial, and Immune Determinants​. Journal of Visualized Experiments. https://doi.org/10.3791/73743

Vancouver

Wang ZY, Song CC, Jiao Y. Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease Beyond Fibrosis: Metabolic, Microbial, and Immune Determinants​. Journal of Visualized Experiments. 2026. doi:10.3791/73743

BibTeX
@article{Wang2026,
  author = {Wang, Zheng-Ying and Song, Cheng-Cheng and Jiao, Yan},
  title = {Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease Beyond Fibrosis: Metabolic, Microbial, and Immune Determinants​},
  journal = {Journal of Visualized Experiments},
  year = {2026},
  doi = {10.3791/73743}
}
Start for free →